NDB

NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research[1].

Product Specifications

CAS Number

[1660153-08-1]

UNSPSC

12352005

Target

FXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ndb.html

Purity

98.36

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(C1=CC=C(O)C(C(C)(C)C)=C1)CC2=CC=CC=C2)C3=C(Cl)C=C(N(C)C)C=C3Cl

Molecular Formula

C26H28Cl2N2O2

Molecular Weight

471.42

References & Citations

[1]Xing Xu, et al. Structural Basis for Small Molecule NDB (N-Benzyl-N- (3- (tert-butyl) -4-hydroxyphenyl) -2,6-dichloro-4- (dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor. J Biol Chem. 2015 Aug 7;290 (32) :19888-99.